InflaRx's INF904 Will Initially Target Chronic Spontaneous Urticaria And Hidradenitis Suppurativa, With Initiation Of A Phase 2a PK Dose-ranging Study Expected By The End Of 2024, With Data Availability Anticipated In 2025
InflarX 的 INF904 最初將針對慢性自發性蕁麻疹和化膿性汗腺炎,預計將於 2024 年底啓動 2a 期 PK 劑量範圍研究,預計將於 2025 年提供數據